口服左西孟旦治疗肌萎缩侧索硬化:REFALS随机双盲安慰剂对照3期试验
REFALS是一项在14国99个ALS专科中心开展的随机双盲安慰剂对照3期试验,纳入坐位慢肺活量为预测值60-90%的ALS患者496例,按2:1分配至口服左西孟旦组或安慰剂组。12周仰卧位慢肺活量相对基线的变化两组无显著差异,48周功能与生存联合评估亦无差异;左西孟旦总体耐受,但心动过速和头痛更常见。
要点
- 口服左西孟旦未能优于安慰剂维持ALS患者呼吸功能。
- 12周仰卧位SVC变化两组差异无统计学意义。
- 心动过速和头痛在左西孟旦组发生更频繁。
核心结论
- 口服左西孟旦在广泛ALS人群中维持呼吸功能方面不优于安慰剂。
- 左西孟旦总体耐受良好,但心动过速和头痛较安慰剂更常见。
- 是否存在临床相关的应答亚组人群尚需进一步评估。
研究设计与样本
- REFALS为随机、双盲、安慰剂对照3期试验,在14个国家99个ALS专科中心开展。
- 纳入年龄≥18岁、坐位慢肺活量(SVC)为预测值60-90%的ALS患者。
- 496例受试者按2:1随机分配至左西孟旦组(n=329)或安慰剂组(n=167)。
- 主要终点为12周仰卧位SVC相对基线的变化(以预测正常坐位SVC百分比评估)。
- 关键次要终点为至48周的功能与生存联合评估(CAFS)。
主要发现
- 最常见不良事件为心率增快(左西孟旦组106/326[33%] vs 安慰剂组12/166[7%])、跌倒(85[26%] vs 48[29%])、头痛(93[29%] vs 36[22%])和呼吸困难(59[18%] vs 32[19%])。
- 试验期间左西孟旦组33例(10%)、安慰剂组20例(12%)死亡,主要死因为呼吸衰竭或ALS进展。
关键数值与推荐
- 入组条件为坐位SVC为预测值的60-90%。
临床怎么用
- 本研究结果不支持口服左西孟旦用于广泛ALS人群维持呼吸功能。
- 用药时需关注心率增快和头痛等不良反应。
- 对潜在应答亚组的识别有待进一步研究。
局限性
- 研究纳入坐位SVC为预测值60-90%的人群,结论不能外推至其他呼吸功能范围的患者。
- 扩展研究REFALS-ES结果另行报告,本文未纳入其数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an urgent unmet need for new therapies in amyotrophic lateral sclerosis. In a clinical study with healthy volunteers, levosimendan, a calcium sensitiser, was shown to improve neuromechanical efficiency and contractile function of the human diaphragm. We aimed to evaluate the safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis, with a focus on respiratory function. METHODS: The REFALS study is a randomised, double-blind, placebo-controlled phase 3 trial at 99 amyotrophic lateral sclerosis specialist centres in 14 countries worldwide. People with amyotrophic lateral sclerosis were eligible for participation if they were at least 18 years of age and had a sitting slow vital capacity (SVC) of 60-90% predicted. Participants were randomly assigned (2:1) by interactive web-response system to receive either levosimendan or placebo. The capsules for oral administration were identical in appearance to maintain blinding of participants and investigators. The primary endpoint was the change from baseline in supine SVC at 12 weeks, assessed as the percentage of predicted normal sitting SVC. The key secondary endpoint was the combined assessment of function and survival (CAFS) up to 48 weeks. Analyses were done in the intention-to-treat population, comprising all participants who were randomly assigned. This trial is registered at ClinicalTrials.gov (NCT03505021) and has been completed. An extension study (REFALS-ES; NCT03948178) has also been completed, but will be reported separately. FINDINGS: Between June 21, 2018, and June 28, 2019, 871 people were screened for the study, of whom 496 were randomly assigned either levosimendan (n=329) or placebo (n=167). Participants were followed up between June 27, 2018 and June 26, 2020, for a median duration of 50·1 (IQR 37·5-51·1) weeks. The median duration of treatment was 47·9 (IQR 26·4-48·1) weeks. Change from baseline in supine SVC at 12 weeks was -6·73% with levosimendan and -6·99% with placebo, with no significant difference between the treatments (estimated treatment difference 0·26%, 95% CI -2·03 to 2·55, p=0·83). Similarly, at week 48, CAFS did not differ between treatment groups (least squares mean change from baseline 10·69, 95% CI -15·74 to 37·12; nominal p value=0·43). The most frequent adverse events were increased heart rate (106 [33%] of 326 receiving levosimendan vs 12 [7%] of 166 receiving placebo), fall (85 [26%] vs 48 [29%]), headache (93 [29%] vs 36 [22%]), and dyspnoea (59 [18%] vs 32 [19%]). 33 (10%) participants allocated levosimendan and 20 (12%) assigned placebo died during the trial, mainly due to respiratory failure or progression of amyotrophic lateral sclerosis. INTERPRETATION: Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo. The possibility of a clinically relevant subgroup of responsive individuals requires further evaluation. FUNDING: Orion Corporation.
引用
- Cudkowicz M, Genge A, Maragakis N, et al. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021. PMID: 34536404. doi:10.1016/S1474-4422(21)00242-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。